Brentuximab Vedotin for Treating CD30-Positive Hodgkin Lymphoma (TA446)

Technology Appraisal Guidance No. 446

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Brentuximab vedotin is recommended as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:

they have relapsed or refractory disease after autologous stem cell transplant and

the company provides brentuximab vedotin at the price agreed with NHS England in the commercial access agreement.

1.2 Brentuximab vedotin is recommended for use within the Cancer Drugs Fund as an option for treating CD30-positive Hodgkin lymphoma in adults, only if:

  • they have relapsed or refractory disease after at least 2 previous therapies and
  • they cannot have autologous stem cell transplant or multi-agent chemotherapy and
  • the conditions of the managed access agreement are followed.

1.3 These recommendations are not intended to affect treatment with brentuximab vedotin that was started in the NHS before this guidance was published. Adults having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

A copy of the full document and background is available on the Internet at

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma.
Issue Date: June 2017

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more